|1.||Akram, Ali: 2 articles (06/2014 - 12/2013)|
|2.||Inman, Robert D: 2 articles (06/2014 - 12/2013)|
|3.||Mohanakumar, T: 2 articles (05/2011 - 10/2003)|
|4.||Stambrook, Peter J: 2 articles (04/2004 - 04/2003)|
|5.||Li, Ya-Qin: 2 articles (04/2004 - 04/2003)|
|6.||Gleich, Lyon L: 2 articles (04/2004 - 04/2003)|
|7.||Gleich, L L: 2 articles (07/2001 - 05/2000)|
|8.||Lin, Aifeng: 1 article (06/2014)|
|9.||Streutker, Catherine J: 1 article (06/2014)|
|10.||Gracey, Eric: 1 article (06/2014)|
|1.||Melanoma (Melanoma, Malignant)
01/01/1997 - "To determine the safety, toxicity, and efficacy of direct intratumoral injection of an allogeneic major histocompatibility complex (MHC) class I gene, HLA-B7, in a cationic lipid vector (Allovectin-7; Vical Inc, San Diego, CA) in patients with metastatic melanoma. "
09/01/1996 - "Tumor-infiltrating lymphocytes (TIL) were isolated from cutaneous melanoma biopsies before and after HLA-B7 gene transfer. "
09/01/1996 - "Hence, melanoma nodules were directly injected with a vector encoding an allogeneic MHC class I molecule, HLA-B7. "
02/01/1980 - "An alien HLA-B7 was detected in sera from two melanoma patients. "
01/01/1997 - "Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma."
|2.||Head and Neck Neoplasms (Head and Neck Cancer)
04/01/2003 - "Human trials of alloantigen gene therapy, using the class I major histocompatibility complex (MHC) HLA-B7, have demonstrated the potential efficacy of this treatment for head and neck cancer. "
05/01/2000 - "Twenty patients with advanced head and neck cancer who had failed conventional therapy and did not express HLA-B7 were treated with gene therapy using a lipid vector by direct intratumoral injection. "
04/01/2004 - "Alloantigen gene therapy with the genes for the Class I major histocompatibility complex (MHC) HLA-B7 and beta 2-microglobulin in HLA-B7-negative patients has potential efficacy in the treatment of head and neck cancer, although the mechanism of response is unclear. "
03/01/2009 - "The expression of HLA-B7 and CD54 on tumor cells increases upon cytokine stimulation resulting in improved T cell activation as observed by higher levels of degranulation and enhanced tumor cell lysis. "
02/01/2009 - "The tumor epitope bound to HLA-B7 by bulging outward from the peptide-binding cleft. "
12/01/2006 - "In sequence, we used algorithm-based predictions, in vivo immunization of HLA-B7 transgenic (Tg) mice, in vitro immunization of human blood lymphocytes from two normal donors and two cancer patients, in vivo processing in HLA-B7 Tg mice and HLA-B7 supertype binding. "
07/01/2002 - "The mean expression of HLA-B7 by autologous tumor cells after gene transfer was 4.53% (range 0.3%-12.1%). "
09/15/2000 - "These CTLs were efficient in killing tumor cells that express HLA-B7 and produce CEA. "
|4.||Breast Neoplasms (Breast Cancer)
07/01/2009 - "These results suggest that the MICA-A5 allele appears to confer protection against human breast cancer and that the MICA-A5.1 appears to increase the susceptibility to breast cancer in HLA-B7 patients in our area."
11/15/2005 - "These results support previous suggestions that HLA-B7 is associated with the development of breast cancer in our area."
11/15/2005 - "The HLA-B7 allele confers susceptibility to breast cancer in Spanish women."
11/01/1979 - "A greater incidence of HLA-B7 and B26 was observed in the breast cancer group if compared with the frequency of occurrence of these antigens in the Spanish population. "
05/01/2011 - "In summary, our results define HLA-B7-restriced, MGBA-derived, CD8(+) CTL epitopes with all of the necessary features for developing novel vaccine strategies against HLA-B7 expressing breast cancer patients."
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/01/1998 - "Nine patients with advanced head and neck squamous cell carcinoma who had failed conventional therapy and did not express HLA-B7, a class I major histocompatibility complex protein. "
07/01/2001 - "To investigate the safety and efficacy of alloantigen plasmid DNA therapy in patients with advanced head and neck squamous cell carcinoma using Allovectin-7 (Vical Inc, San Diego, Calif), a DNA/lipid complex designed to express the class I major histocompatibility complex antigen HLA-B7. "
|3.||A-Form DNA (A-DNA)
|4.||Histocompatibility Antigens (Histocompatibility Antigen)
|6.||HLA-B8 Antigen (HLA B8 Antigen)
|7.||HLA Antigens (Human Leukocyte Antigens)
|8.||HLA-DRB1 antigen (HLA DRB1)
|9.||Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)
|10.||HLA-DR3 Antigen (HLA DR3 Antigen)